Enhanced survival in locoregionally confined anaplastic thyroid carcinoma

A single-institution experience using aggressive multimodal therapy

Robert L. Foote, Julian R Molina, Jan Kasperbauer, Ricardo V. Lloyd, Bryan McIver, John C. Morris, Clive S. Grant, Geoffrey B. Thompson, Melanie L. Richards, Ian D Hay, Robert Christian Smallridge, Keith C. Bible

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Background: Historical outcomes in anaplastic thyroid carcinoma (ATC) are poor, with a median survival of only 5 months and <20% of patients surviving 1 year from diagnosis. We hypothesized that survival in newly diagnosed patients with stages IVA and IVB locoregionally confined ATC might be improved by utilizing an aggressive therapeutic approach, prioritizing both the eradication of disease in the neck and preemptive treatment of occult metastatic disease. Methods: Between January 1, 2003, and December 31, 2007, 25 new ATC patients were evaluated at our institution. Of these 25 patients, 10 (40%) had metastatic disease at diagnosis and therefore underwent palliative treatment, whereas 5 (20%) had regionally confined disease and desired treatment at their local medical facilities. The remaining 10 consecutive patients (40%) had regionally confined ATC and elected aggressive therapy combining individualized surgery (where feasible), intensity-modulated radiation therapy (IMRT), and radiosensitizing + adjuvant chemotherapy intending four cycles of docetaxel + doxorubicin. Outcomes were assessed on an intention to treat basis. Results: There were no deaths from therapy, but hospitalization was required in two patients (20%) because of treatment-related adverse events. Five patients (50%) are alive and cancer-free, all having been followed >32 months (range: 32-89 months; median: 44 months) with a median overall Kaplan-Meier survival of 60 months. Overall survival at 1 and 2 years was 70% and 60%, respectively, compared to <20% historical survival at 1 year in analogous patients previously treated with surgery and conventional postoperative radiation at our and other institutions. Conclusions: Although based upon a small series of consecutively treated patients, an aggressive approach combining IMRT and radiosensitizing plus adjuvant chemotherapy appears to improve outcomes, including survival in stages IVA and IVB regionally confined ATC, but remains of uncertain benefit in patients with stage IVC (metastatic) disease. Also uncertain is the optimal chemotherapy regimen to use in conjunction with IMRT. Further multicenter randomized trials are required to define optimal therapy in this rare but deadly cancer.

Original languageEnglish (US)
Pages (from-to)25-30
Number of pages6
JournalThyroid
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Survival
Therapeutics
Adjuvant Chemotherapy
Multicenter Studies
Anaplastic Thyroid Carcinoma
Radiation
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Enhanced survival in locoregionally confined anaplastic thyroid carcinoma : A single-institution experience using aggressive multimodal therapy. / Foote, Robert L.; Molina, Julian R; Kasperbauer, Jan; Lloyd, Ricardo V.; McIver, Bryan; Morris, John C.; Grant, Clive S.; Thompson, Geoffrey B.; Richards, Melanie L.; Hay, Ian D; Smallridge, Robert Christian; Bible, Keith C.

In: Thyroid, Vol. 21, No. 1, 01.01.2011, p. 25-30.

Research output: Contribution to journalArticle

Foote, Robert L. ; Molina, Julian R ; Kasperbauer, Jan ; Lloyd, Ricardo V. ; McIver, Bryan ; Morris, John C. ; Grant, Clive S. ; Thompson, Geoffrey B. ; Richards, Melanie L. ; Hay, Ian D ; Smallridge, Robert Christian ; Bible, Keith C. / Enhanced survival in locoregionally confined anaplastic thyroid carcinoma : A single-institution experience using aggressive multimodal therapy. In: Thyroid. 2011 ; Vol. 21, No. 1. pp. 25-30.
@article{9e335947f5f149be9f016062e47b5a5b,
title = "Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: A single-institution experience using aggressive multimodal therapy",
abstract = "Background: Historical outcomes in anaplastic thyroid carcinoma (ATC) are poor, with a median survival of only 5 months and <20{\%} of patients surviving 1 year from diagnosis. We hypothesized that survival in newly diagnosed patients with stages IVA and IVB locoregionally confined ATC might be improved by utilizing an aggressive therapeutic approach, prioritizing both the eradication of disease in the neck and preemptive treatment of occult metastatic disease. Methods: Between January 1, 2003, and December 31, 2007, 25 new ATC patients were evaluated at our institution. Of these 25 patients, 10 (40{\%}) had metastatic disease at diagnosis and therefore underwent palliative treatment, whereas 5 (20{\%}) had regionally confined disease and desired treatment at their local medical facilities. The remaining 10 consecutive patients (40{\%}) had regionally confined ATC and elected aggressive therapy combining individualized surgery (where feasible), intensity-modulated radiation therapy (IMRT), and radiosensitizing + adjuvant chemotherapy intending four cycles of docetaxel + doxorubicin. Outcomes were assessed on an intention to treat basis. Results: There were no deaths from therapy, but hospitalization was required in two patients (20{\%}) because of treatment-related adverse events. Five patients (50{\%}) are alive and cancer-free, all having been followed >32 months (range: 32-89 months; median: 44 months) with a median overall Kaplan-Meier survival of 60 months. Overall survival at 1 and 2 years was 70{\%} and 60{\%}, respectively, compared to <20{\%} historical survival at 1 year in analogous patients previously treated with surgery and conventional postoperative radiation at our and other institutions. Conclusions: Although based upon a small series of consecutively treated patients, an aggressive approach combining IMRT and radiosensitizing plus adjuvant chemotherapy appears to improve outcomes, including survival in stages IVA and IVB regionally confined ATC, but remains of uncertain benefit in patients with stage IVC (metastatic) disease. Also uncertain is the optimal chemotherapy regimen to use in conjunction with IMRT. Further multicenter randomized trials are required to define optimal therapy in this rare but deadly cancer.",
author = "Foote, {Robert L.} and Molina, {Julian R} and Jan Kasperbauer and Lloyd, {Ricardo V.} and Bryan McIver and Morris, {John C.} and Grant, {Clive S.} and Thompson, {Geoffrey B.} and Richards, {Melanie L.} and Hay, {Ian D} and Smallridge, {Robert Christian} and Bible, {Keith C.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1089/thy.2010.0220",
language = "English (US)",
volume = "21",
pages = "25--30",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Enhanced survival in locoregionally confined anaplastic thyroid carcinoma

T2 - A single-institution experience using aggressive multimodal therapy

AU - Foote, Robert L.

AU - Molina, Julian R

AU - Kasperbauer, Jan

AU - Lloyd, Ricardo V.

AU - McIver, Bryan

AU - Morris, John C.

AU - Grant, Clive S.

AU - Thompson, Geoffrey B.

AU - Richards, Melanie L.

AU - Hay, Ian D

AU - Smallridge, Robert Christian

AU - Bible, Keith C.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: Historical outcomes in anaplastic thyroid carcinoma (ATC) are poor, with a median survival of only 5 months and <20% of patients surviving 1 year from diagnosis. We hypothesized that survival in newly diagnosed patients with stages IVA and IVB locoregionally confined ATC might be improved by utilizing an aggressive therapeutic approach, prioritizing both the eradication of disease in the neck and preemptive treatment of occult metastatic disease. Methods: Between January 1, 2003, and December 31, 2007, 25 new ATC patients were evaluated at our institution. Of these 25 patients, 10 (40%) had metastatic disease at diagnosis and therefore underwent palliative treatment, whereas 5 (20%) had regionally confined disease and desired treatment at their local medical facilities. The remaining 10 consecutive patients (40%) had regionally confined ATC and elected aggressive therapy combining individualized surgery (where feasible), intensity-modulated radiation therapy (IMRT), and radiosensitizing + adjuvant chemotherapy intending four cycles of docetaxel + doxorubicin. Outcomes were assessed on an intention to treat basis. Results: There were no deaths from therapy, but hospitalization was required in two patients (20%) because of treatment-related adverse events. Five patients (50%) are alive and cancer-free, all having been followed >32 months (range: 32-89 months; median: 44 months) with a median overall Kaplan-Meier survival of 60 months. Overall survival at 1 and 2 years was 70% and 60%, respectively, compared to <20% historical survival at 1 year in analogous patients previously treated with surgery and conventional postoperative radiation at our and other institutions. Conclusions: Although based upon a small series of consecutively treated patients, an aggressive approach combining IMRT and radiosensitizing plus adjuvant chemotherapy appears to improve outcomes, including survival in stages IVA and IVB regionally confined ATC, but remains of uncertain benefit in patients with stage IVC (metastatic) disease. Also uncertain is the optimal chemotherapy regimen to use in conjunction with IMRT. Further multicenter randomized trials are required to define optimal therapy in this rare but deadly cancer.

AB - Background: Historical outcomes in anaplastic thyroid carcinoma (ATC) are poor, with a median survival of only 5 months and <20% of patients surviving 1 year from diagnosis. We hypothesized that survival in newly diagnosed patients with stages IVA and IVB locoregionally confined ATC might be improved by utilizing an aggressive therapeutic approach, prioritizing both the eradication of disease in the neck and preemptive treatment of occult metastatic disease. Methods: Between January 1, 2003, and December 31, 2007, 25 new ATC patients were evaluated at our institution. Of these 25 patients, 10 (40%) had metastatic disease at diagnosis and therefore underwent palliative treatment, whereas 5 (20%) had regionally confined disease and desired treatment at their local medical facilities. The remaining 10 consecutive patients (40%) had regionally confined ATC and elected aggressive therapy combining individualized surgery (where feasible), intensity-modulated radiation therapy (IMRT), and radiosensitizing + adjuvant chemotherapy intending four cycles of docetaxel + doxorubicin. Outcomes were assessed on an intention to treat basis. Results: There were no deaths from therapy, but hospitalization was required in two patients (20%) because of treatment-related adverse events. Five patients (50%) are alive and cancer-free, all having been followed >32 months (range: 32-89 months; median: 44 months) with a median overall Kaplan-Meier survival of 60 months. Overall survival at 1 and 2 years was 70% and 60%, respectively, compared to <20% historical survival at 1 year in analogous patients previously treated with surgery and conventional postoperative radiation at our and other institutions. Conclusions: Although based upon a small series of consecutively treated patients, an aggressive approach combining IMRT and radiosensitizing plus adjuvant chemotherapy appears to improve outcomes, including survival in stages IVA and IVB regionally confined ATC, but remains of uncertain benefit in patients with stage IVC (metastatic) disease. Also uncertain is the optimal chemotherapy regimen to use in conjunction with IMRT. Further multicenter randomized trials are required to define optimal therapy in this rare but deadly cancer.

UR - http://www.scopus.com/inward/record.url?scp=78651291649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651291649&partnerID=8YFLogxK

U2 - 10.1089/thy.2010.0220

DO - 10.1089/thy.2010.0220

M3 - Article

VL - 21

SP - 25

EP - 30

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 1

ER -